Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

被引：25
|
作者：
Scharrer, I
Ehrlich, HJ
机构：
[1] Univ Hosp Frankfurt, Ctr Internal Med, D-60596 Frankfurt, Germany
[2] Baxter Hyland Immuno, Vienna, Austria
来源：
HAEMOPHILIA | 2001年 / 7卷 / 04期
关键词：
blood coagulation factor inhibitors; clinical trials; factor VIII; haemophilia A; incidence; recombinant proteins;
D O I：
10.1046/j.1365-2516.2001.00515.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.
引用
收藏
页码：346 / 348
页数：3
相关论文
共 50 条
  • [31] Pharmacokinetics (PK) of recombinant and plasma-derived factor VIII (FVIII) products in pediatric patients with severe hemophilia A
    Steele, M.
    Chan, A.
    Nagel, K.
    HAEMOPHILIA, 2012, 18 : 35 - 35
  • [32] Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
    Miri, Syna
    Rosendaal, Frits R.
    Kavakli, Kaan
    Eshghi, Peyman
    Moghaddam, Soha Mohammadi
    Scardo, Sara
    Habibpanah, Behnaz
    Elalfy, Mohsen
    Halimeh, Susan
    Nicolo, Gabriella
    Gokcebay, Dilek
    Ozbek, Namik
    Celkan, Tiraje
    Mohammadi, Ahmad
    Karimi, Mehran
    Shahsavani, Amin
    Yilmaz, Baris
    Albayrak, Canan
    Gunes, Burcak
    Kaya, Zuehre
    Ay, Yilmaz
    Akbayram, Sinan
    Sarper, Nazan
    Mannucci, Pier Mannuccio
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [33] FACTOR-VIII INHIBITOR ASSAYS USING PLASMA-DERIVED FVIII VERSUS RECOMBINANT FVIII - A COMPARATIVE-STUDY
    HILLMANWISEMAN, C
    VITALE, C
    LUSHER, J
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 684 - 684
  • [34] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIII ARE IMMUNOLOGICALLY DISTINCT IN IN-VITRO ASSAYS
    GILLES, JGG
    SAINTREMY, JMR
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1213 - 1213
  • [35] The Use of Plasma-Derived Factor VIII in Two Patients Diagnosed with TTP
    Kaya, Mehmet Nur
    Ilhan, Gul
    Kaya, Hasan
    CYPRUS JOURNAL OF MEDICAL SCIENCES, 2022, 7 (06): : 812 - 814
  • [36] The binding kinetics of B-domain-deleted recombinant factor VIII and plasma-derived factor VIII to phospholipid vesicles
    Brekkan, E
    Wrangel, M
    Sandberg, H
    THROMBOSIS AND HAEMOSTASIS, 1999, : 235 - 235
  • [37] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL
    TURECEK, PL
    SCHWARZ, HP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 986 - 986
  • [38] Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?
    Messori, Andrea
    Fadda, Valeria
    Maratea, Dario
    Trippoli, Sabrina
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 269 - 270
  • [39] ECONOMIC IMPACT OF TREATING SEVERE HEMOPHILIA A PATIENTS WITH PLASMA-DERIVED FACTOR-VIII/VWF VERSUS RECOMBINANT FACTOR-VIII IN THE UNITED STATES
    O'Day, K.
    Runken, M. C.
    Meyer, K. L.
    Spears, J. B.
    VALUE IN HEALTH, 2017, 20 (05) : A216 - A217
  • [40] Response to "Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?"
    Franchini, Massimo
    Mengoli, Carlo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 271 - 272
12345